newsfilter
← Latest News
PR Newswire·

AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST).
  • Aquestive shares dropped approximately 40% intraday after the FDA identified deficiencies in its New Drug Application for Anaphylm.
  • The FDA stated that unidentified deficiencies currently prevent discussions regarding labeling & post-marketing requirements.
  • These issues raise concerns about the application's approvability ahead of the January 31, 2026, PDUFA action date.
  • James (Josh) Wilson, a Senior Partner at the firm, is encouraging investors with significant losses to contact him directly.
  • Investors may reach Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) or visit www.faruqilaw.com/AQST for more information.
  • The law firm has recovered hundreds of millions of dollars for investors since its founding in 1995.